国際医薬品開発研究ジャーナル

  • ISSN: 0975-9344
  • ジャーナル h-index: 44
  • 雑誌引用スコア: 59.93
  • ジャーナルのインパクトファクター: 48.80
インデックス付き
  • Genamics JournalSeek
  • 中国国家知識基盤 (CNKI)
  • サイテファクター
  • シマゴ
  • 研究ジャーナル索引作成ディレクトリ (DRJI)
  • OCLC-WorldCat
  • パブロン
  • ミアル
  • 大学補助金委員会
  • ユーロパブ
  • Google スカラー
  • シェルパ・ロメオ
  • 秘密検索エンジン研究所
  • リサーチゲート
このページをシェアする

抽象的な

Targeting Tumour Blood Vessels with a Liposomal Drug Delivery system for Cancer Treatment

Naghmeh Shahraki*

By providing various drug delivery methods and controlled-release distribution tactics, nanotechnology provides an alternative to traditional treatment alternatives. Due to their high biodegradability and general lack of toxicity, liposomes provide a flexible platform for a number of various delivery strategies that may improve the distribution and targeting of medicines to tumours. Due to fenestrated blood arteries within tumours, liposomes spontaneously enter tumours, causing recognised increased permeability and associated medication retention effects. Liposomes are appealing carriers for molecular imaging applications because they can be utilised to transport radioactive moieties, such as radiotracers, which can be bound at various points inside liposomes. Using the phage display method, various high-affinity and selectivity peptides can be delivered to various targets. In this study, covalent peptide-PEG-PE anchors were used to link gelatinase-binding peptides discovered by phage display to liposomes, resulting in a tailored drug delivery vehicle. A good approach for tumour targeting is to use gelatinases as extracellular targets. Based on our research, focused drug delivery outperforms non-targeted drug delivery in terms of effectiveness.

Keywords

Liposome; Transparent tumor; Blood vessels; Nanotechnology; Anticancer agents; Targeted drug delivery